Business Context and Reporting Period
This Form 8-K is a current report filed by Revelation Biosciences, Inc. on November 23, 2022. The filing addresses a critical regulatory event regarding the company's continued listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, or cash flow data. However, it references specific equity figures from prior reports:
- Stockholders' Deficit (Q1 2022): $98,511 (reported in Form 10-Q for the quarter ended March 31, 2022).
- Stockholders' Equity (Q3 2022): $2,227,768 (reported in Form 10-Q for the quarter ended September 30, 2022).
- Capital Raise (July 2022): $5 million completed.
- Nasdaq Equity Requirement: $2,500,000 minimum.
Material Changes and Events
The primary material event is the receipt of a "Second Nasdaq Letter" on November 23, 2022, notifying the company of its failure to regain compliance with Nasdaq Listing Rule 5550(b)(1) regarding the minimum stockholders' equity requirement.
- Initial Deficiency: Received on May 24, 2022, due to a stockholders' deficit.
- Compliance Plan: The company submitted a plan to raise $10 million and was granted an extension until November 21, 2022.
- Outcome: Despite raising $5 million in July 2022, the company's equity remained below the $2.5 million threshold as of September 30, 2022.
- Consequence: Nasdaq has scheduled a suspension of trading for the company's securities (Units, Common Stock, and Warrants) to begin on the opening of business on December 2, 2022.
Outlook, Risks, and Management Commentary
Management intends to take all reasonable measures to regain compliance. The company plans to appeal the Second Nasdaq Letter by requesting a hearing before an independent panel.
- Appeal Process: A hearing request would stay the suspension pending the conclusion of the hearing and any potential extension granted by the panel.
- Risks: There is no assurance that the hearing panel will grant an extension or that the company will ultimately regain compliance with listing requirements.
- Current Trading Status: As of the filing date, the securities continue to trade on The Nasdaq Capital Market under symbols REVBU, REVB, and REVBW.
Investor Verification Checklist
- Verify the status of the appeal hearing request and any subsequent rulings from the Nasdaq independent panel.
- Monitor the company's ability to raise additional capital to meet the $2.5 million stockholders' equity requirement.
- Confirm the trading status of REVBU, REVB, and REVBW on or after December 2, 2022, to determine if the suspension is enacted.
- Review the most recent Form 10-Q (Q3 2022) for detailed financial position and cash burn rates.